Abbott Laboratories (ABT) operating KPIs
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories rebates & Chargebacks Charged Against Gross Sales ($M) ($M)
Concentrated in Nutritional Products (WIC state contracts) and Diabetes Care (FreeStyle Libre pharmacy/PBM rebates).
Latest, FY2025
4,800
Period ended Dec 31, 2025
Change on a year earlier
+9.1%
4,400 in FY2024
History
15 years
Since FY2011
Sources
13
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up rebates & chargebacks charged against gross sales ($m)
- Consolidated Gross Sales Subject to Rebate ($M)22,500 · FY2025
- Rebates & Chargebacks as % of Gross Sales Subject to Rebate (%)21.1% · FY2025
- Share of Consolidated Gross Revenues Subject to Rebates & Allowances (%)44.0% · FY2025
- Net Sales Impact of 1-Percentage-Point Increase in Rebate Rate ($M)225 · FY2025
- Cash Discounts Charged Against Gross Sales ($M)316 · FY2025
- Product Returns Allowance Charged Against Gross Sales ($M)236 · FY2025
Cite this data
StockData. (2026). Abbott Laboratories Rebates & Chargebacks Charged Against Gross Sales ($M) ($M), annual FY2011–FY2025 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/rebate-charged-m
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.